['influenza']
['oseltamivir', 'medi8852', 'placebo']

        Inclusion Criteria:

          -  Age 18 through 65 years at the time of screening.

          -  Symptomatic presumptive Influenza A infection with onset of symptoms less than or
             equal to (≤) 5 days prior to MEDI8852 administration and defined as the presence of:

          -  Fever of greater than or equal to (≥) 38.0 degrees Celsius (100.4 degrees Fahrenheit)
             at screening AND

          -  ≥ 1 moderate systemic symptom (headache, malaise, myalgia, sweats and/or chills, or
             fatigue) AND

          -  ≥ 1 moderate respiratory symptom (cough, sore throat, or nasal symptoms)

          -  Influenza A infection confirmed with positive rapid antigen test

          -  Able to complete the follow-up period through Day 101 as required by protocol
             (including telephone follow-up for Days 11 to 101)

          -  Females of childbearing potential who are sexually active with a nonsterilized male
             partner must use a highly effective method of contraception for at least 2 days prior
             to the first dose of investigational product and must agree to continue using such
             precautions through Day 101 of the study

        Exclusion Criteria:

          -  Hospitalized subjects.

          -  Receipt of influenza antiviral therapy within the preceding 14 days.

          -  Receipt of immunoglobulin or blood products within 6 months prior to screening.

          -  Known immunodeficiency due to illness, including human immunodeficiency virus (HIV),
             or due to drugs, including any course of glucocorticoid therapy exceeding 2 weeks of
             prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months
             prior to screening.

          -  Current clinical evidence of pneumonia.

          -  Active bacterial infection requiring treatment with oral or parenteral antibiotics.

          -  History of malignancy other than treated non-melanoma skin cancers or locally-treated
             cervical cancer in previous 3 years.

          -  Any planned surgical procedure before completion of Day 101.
      